Skip to main content

Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials.

Publication ,  Journal Article
Uhl, GR; Drgon, T; Johnson, C; Rose, JE
Published in: Pharmacogenomics J
April 2009

Twin studies document substantial heritability for successful abstinence from smoking. A genome-wide association study has identified markers whose allele frequencies differ with nominal P<0.005 in nicotine-dependent clinical trial participants who were successful vs unsuccessful in abstaining from smoking; many of these results are also supported by data from two additional samples. More study is required to precisely determine the variance in quitting success that can be accounted for by the single-nucleotide polymorphisms that are currently identified and to precisely classify individuals who may display varying degrees of genetic vs environmental effects into quitters or nonquitters. However, the data at hand do allow us to model the effects of genotypic stratification in smoking cessation trials. We identify relationships between the costs of identifying and genotyping prospective trial participants vs the costs of performing the clinical trials. We quantitate the increasing savings that result from genetically stratified designs as recruiting/genotyping costs go down and trial costs increase. This model helps to define the circumstances in which genetically stratified designs may enhance power and reduce costs for smoking cessation clinical trials.

Duke Scholars

Published In

Pharmacogenomics J

DOI

EISSN

1473-1150

Publication Date

April 2009

Volume

9

Issue

2

Start / End Page

111 / 115

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tobacco Use Disorder
  • Smoking Prevention
  • Smoking Cessation
  • Smoking
  • Phenotype
  • Pharmacology & Pharmacy
  • Patient Selection
  • Models, Genetic
  • Models, Economic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Uhl, G. R., Drgon, T., Johnson, C., & Rose, J. E. (2009). Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials. Pharmacogenomics J, 9(2), 111–115. https://doi.org/10.1038/tpj.2008.10
Uhl, G. R., T. Drgon, C. Johnson, and J. E. Rose. “Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials.Pharmacogenomics J 9, no. 2 (April 2009): 111–15. https://doi.org/10.1038/tpj.2008.10.
Uhl GR, Drgon T, Johnson C, Rose JE. Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials. Pharmacogenomics J. 2009 Apr;9(2):111–5.
Uhl, G. R., et al. “Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials.Pharmacogenomics J, vol. 9, no. 2, Apr. 2009, pp. 111–15. Pubmed, doi:10.1038/tpj.2008.10.
Uhl GR, Drgon T, Johnson C, Rose JE. Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials. Pharmacogenomics J. 2009 Apr;9(2):111–115.

Published In

Pharmacogenomics J

DOI

EISSN

1473-1150

Publication Date

April 2009

Volume

9

Issue

2

Start / End Page

111 / 115

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tobacco Use Disorder
  • Smoking Prevention
  • Smoking Cessation
  • Smoking
  • Phenotype
  • Pharmacology & Pharmacy
  • Patient Selection
  • Models, Genetic
  • Models, Economic